Jane Street Group LLC Raises Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Jane Street Group LLC boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 23.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 99,487 shares of the company's stock after buying an additional 18,573 shares during the period. Jane Street Group LLC owned approximately 0.21% of Amphastar Pharmaceuticals worth $3,694,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in shares of Amphastar Pharmaceuticals by 53.3% in the 3rd quarter. Barclays PLC now owns 74,456 shares of the company's stock valued at $3,613,000 after purchasing an additional 25,878 shares during the last quarter. Arkadios Wealth Advisors lifted its stake in shares of Amphastar Pharmaceuticals by 5.2% in the 4th quarter. Arkadios Wealth Advisors now owns 27,964 shares of the company's stock valued at $1,038,000 after purchasing an additional 1,379 shares during the last quarter. Dakota Wealth Management lifted its stake in shares of Amphastar Pharmaceuticals by 31.7% in the 4th quarter. Dakota Wealth Management now owns 5,486 shares of the company's stock valued at $204,000 after purchasing an additional 1,322 shares during the last quarter. KBC Group NV lifted its stake in shares of Amphastar Pharmaceuticals by 43.1% in the 4th quarter. KBC Group NV now owns 2,159 shares of the company's stock valued at $80,000 after purchasing an additional 650 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock valued at $50,139,000 after purchasing an additional 1,347,775 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Insider Transactions at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares of the company's stock, valued at approximately $2,681,377.02. This represents a 4.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 5,231 shares of company stock worth $142,752 over the last quarter. 27.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

AMPH has been the subject of several analyst reports. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Wells Fargo & Company dropped their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Finally, Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $32.33.

Amphastar Pharmaceuticals Stock Performance

Amphastar Pharmaceuticals stock traded up $0.54 during trading hours on Friday, hitting $24.86. 510,253 shares of the stock traded hands, compared to its average volume of 478,104. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm's 50 day moving average price is $25.43 and its 200-day moving average price is $33.72. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 8.29, a P/E/G ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a 1 year low of $22.64 and a 1 year high of $53.96.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.